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Purpose: The comparison of one-site versus two-site phacotrabeculectomy in patients with 
pseudoexfoliation glaucoma (PEXG) and primary open-angle glaucoma (POAG), with respect 
to intraocular pressure (IOP), antiglaucomatous medication (AM) requirements and visual 
acuity (VA).
Methods: Forty-seven patients (eyes) with cataract and POAG and 46 sex- and age-matched 
patients with cataract and PEXG were randomized to one- or two-site phacotrabeculectomy 
and reviewed with a follow-up at three years.
Results: Mean preoperative IOP was 22.04 ± 2.27 mmHg and 22.92 ± 2.35 mmHg in POAG 
and PEXG groups (p   0.05) using a mean of 2.76 ± 0.74, 2.74 ± 0.69 AM, respectively 
(p   0.05). After three years of follow-up, the mean IOP was 15.04 ± 1.57 mmHg in the 
one-site, 15.04 ± 1.99 mmHg in the two-site group with POAG, 15 ± 1.8 mmHg in the one-site, 
15.32 ± 1.31 mmHg in the two-site group with PEXG, using a mean of 0.68 ± 0.69, 0.84 ± 0.75, 
0.96 ± 0.67, and 0.8 ± 0.62 AM, respectively. Mean IOP and AM postoperatively were signiﬁ  cantly 
less compared to preoperatively for each group (p   0.05). No difference was observed in mean 
IOP and AM between the four groups at three years postoperatively (p   0.05). VA improved 
similarly in four groups at the three-year follow-up (p   0.05). Intraoperative, postoperative 
complications, and need for 5-ﬂ  uorouracil injections were similar between the surgical groups.
Conclusion: One-site and two-site phacotrabeculectomy without the use of antimetabolites 
intraoperatively were similarly safe and effective in IOP control over a three-year follow-up 
period in patients with POAG and PEXG.
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Introduction
The concurrent existence of visually signiﬁ  cant cataract and glaucoma is increasingly 
common in the elderly population. Because of this the ophthalmologist commonly faces 
a surgical decision on the best way to simultaneously manage these two conditions.
Combined cataract extraction, intraocular lens (IOL) implantation, and 
trabeculectomy are now widely accepted for managing cataracts in patients with 
poorly controlled glaucoma. In addition, the intraoperative and postoperative use of 
antimetabolites such as mitomycin C and 5-ﬂ  uorouracil (5-FU) have been shown to 
produce lower intraocular pressure (IOP) after the operation.1–3
Phacotrabeculectomy is performed either with the two procedures (phacoemulsi-
ﬁ  cation and trabeculectomy) through the same incision (one site) or through separate 
incisions (two sites).Clinical Ophthalmology 2009:3 298
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It has been argued that the phacoemulcification 
incision separate from the trabeculectomy incision reduces 
postoperative scarring of the scleral ﬂ  ap and conjuctiva and 
improves the results of the ﬁ  ltration surgery.4
However, the decision to perform phacotrabeculectomy 
through one site or two sites remains controversial. Although 
outcomes in terms of visual acuity (VA) have been similar,5–8 
there is a debate concerning which technique offers the 
best IOP control and reduction in glaucoma medication 
requirements.9–10
Pseudoexfoliation glaucoma (PEXG) has a high incidence 
in the elderly population. Because of this the coexistance 
of PEXG glaucoma and cataract is more likely. PEXG 
glaucoma is generally accepted as being more resistant to 
the treatment (surgical or medicational) compared to primary 
open-angle glaucoma (POAG). However there are no studies 
focusing on the comparison of one site to two-site combined 
phacotrabeculectomy technique in patients with PEXG.
The purpose of this study was to compare prospectively the 
results of one site with two-site combined phacoemulsiﬁ  cation 
with IOL implantation and trabeculectomy surgery without 
the use of antimetabolites intraoperatively with respect to 
VA, IOP, and glaucoma medication requirements in patients 
with POAG and PEXG.
Patients and methods
The clinical outcomes of one-site and two-site phacotra-
beculectomy were compared in a three-year prospective, 
randomized, controlled clinical trial. Patients were recruited 
and enrolled at the Glaucoma Unit of the University Eye 
Clinic of Ioannina, Greece. All operations were performed 
by one surgeon (GK).
Patient enrollment and treatment 
assignment
Criteria for inclusion in the study were the presence of 
cataract and glaucoma. All patients had a visually signiﬁ  cant 
cataract that impaired some of their activities and they were 
also willing to have cataract extraction. The density of the 
cataract was similar among the patients. Moreover some of 
the patients had a decrease in their VA because of cataract 
( 2 lines by the Snellen method) the last preoperative 
months.
All patients had POAG or PEXG in the same eye 
with inadequate control of IOP or requiring two or more 
antiglaucoma medications. All eyes had to have had an IOP 
of more than 21 mmHg on at least one previous examination. 
All patients had typical glaucoma visual defect by automated 
perimetry (Humphrey perimetry threshold 30.2 or 24.2) and 
also progression of glaucoma damage (perimetry testing and 
C/D ratio evaluation) during the last months preoperatively. 
No ocular hypertensives were included in the study. All the 
patients had a minimum preoperative follow up of more than 
a year in the glaucoma unit of our clinic.
Exclusion criteria were the presence of neovascularization 
of the iris or angle, a history of uveitis, phacolytic or 
phacomorphic glaucoma, steroid-induced glaucoma, traumatic 
glaucoma, or previous incisional surgery in the same eye. 
Patients older than 89 years were not included. The authors 
did not enroll patients with co-existing ocular pathology 
that would affect ﬁ  nal VA. Patients were randomized to 
one- or two-site phacotrabeculectomy without the use of 
antimetabolites intraoperatively, using a random numbers 
table. Finally patients with rupture of the posterior capsule 
during the phacoemulsiﬁ  cation that leaded to insertion of 
anterior chamber IOL were also excluded from the study.
Procedures
All operated eyes received peribulbar anesthesia with 2% 
lidocaine without epinephrine and 0.75% bupivacaine. 
Pupils were dilated with topical cyclopentolate 1% and 
phenylephrine 2.5%.
One-site surgery
A 4–0 silk suture was placed under the superior rectus 
muscle and was used to rotate the globe inferiorly. A supe-
rior fornix-based conjunctival ﬂ  ap was made by incising the 
conjunctiva at the limbus and dissecting posteriorly. This 
ﬂ  ap was centered at 12 o’clock and was approximately 6 mm 
in chord length. Electrocautery was used to control episcleral 
bleeding. A limited tenonectomy was performed in most 
patients. A triangular partial-thickness scleral ﬂ  ap was 
mobilized superiorly. A paracentesis then was performed, 
followed by injection of a viscoelastic. A shelved entry into 
the anterior chamber under the scleral ﬂ  ap was made using 
a 3.2-mm blade keratome. Phacoemulsiﬁ  cation then was 
performed. After cortical aspiration and reformation of the 
anterior chamber with viscoelastic, the wound was enlarged 
slightly with a crescent knife. A three-piece foldable acrylic 
intraocular lens was inserted into the capsular bag. After 
aspiration of all viscoelastic and injection of acetylcholine 
to constrict the pupil, a Descemet punch was used to create 
a 1.0-mm diameter sclerostomy under the scleral ﬂ  ap. 
A small basal iridectomy was performed in all cases and 
a 10–0 nylon suture was placed at the apex of the ﬂ  ap and 
looped aside.Clinical Ophthalmology 2009:3 299
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The conjunctival incision was closed by passing sutures 
of 8–0 silk into limbal cornea at 10 o’clock and 2 o’clock. 
The anterior edge of the conjunctiva was advanced at least 
1 mm over the cornea to decrease the risk of leakage.
Anterior chamber was deepened with a balanced salt 
solution through the paracentesis with good bleb elevation 
and no bleb leakage.
Antibiotic injection was performed intracamelar and a 
subconjunctival injection of dexamethasone was performed 
inferiorly. Drops of and pilocarpine 1% were applied to the 
cornea before placement of a patch and shield. A single 500-mg 
dose of oral acetazolamide was given in the recovery room to 
every patient unless a sulfa allergy was documented.
Two-site surgery
Two-site surgery began with the surgeon seated temporally. 
A paracentesis was made, followed by injection of visco-
elastic. A temporal clear corneal incision was made with a 
3.2-mm blade keratome. Phacoemulsiﬁ  cation and intraocular 
lens implantation then was performed as described for the 
one-site surgery. The surgeon then switched position and was 
seated superiorly for the trabeculectomy. A 4–0 silk suture 
was passed through superior corneal tissue to rotate the globe 
downward and laterally. A fornix-based conjunctival ﬂ  ap was 
created and a limited tenonectomy was performed in most 
cases. After applying light electrocautery and exposing the con-
junctival insertion anteriorly at the limbus, a triangular scleral 
ﬂ  ap was fashioned as described for the one-site surgery.
With a crescent knife under the scleral ﬂ  ap, the dissection 
then was advanced into clear cornea. The anterior chamber 
was entered with a 3.2-mm blade keratome under the anterior 
hinge of the scleral ﬂ  ap. The sclerostomy, iridectomy, and 
scleral ﬂ  ap closure were performed in the same manner as 
for the one-site surgery. The conjunctival wound was closed 
with 8–0 silk suture. Injections and topical medications then 
were administered as with the one-site eyes.
The postoperative regimen for both groups of eyes was 
identical.
A topical antibiotic and were given three times daily for 
two weeks. Topical corticosteroids and nonsteroidal anti-
inﬂ  ammatory medication were used three times daily for 
the ﬁ  rst month, reduced gradually to two times daily for two 
weeks and then were tapered slowly. Adjunctive topical and 
oral antiglaucoma medications were used as needed for the 
ﬁ  rst one or two weeks.
Data collection
Baseline data including IOP by Goldmann applanation 
tonometry and the number of topical and oral antiglaucoma 
medications used by the patient were recorded before surgery. 
The timolol and dorzolamide combination was considered 
to be two medications. Best-corrected VA was measured 
by the Snellen method. Other information collected before 
surgery included age, gender, diagnostic type of glaucoma, 
and history of previous laser trabeculoplasty or iridotomy. 
Data collected during surgery included operative time and 
complications.
Data were collected at each postoperative visit (included 
IOP, number of supplemental antiglaucoma medications, 
best-corrected VA, occurrence and nature of any complica-
tions) by two different ophthalmologists of the glaucoma 
unit, who did not know the preoperative clinical record of 
the patients. All the data (preoperative and postoperative) 
were analyzed at the end of the follow up.
Five subconjuctival injections of 5-FU (0.1 ml–
50 mg/ml) were performed into the inferior fornix daily 
when IOP was higher than 18 mmHg between 2–3 weeks 
postoperatively.
SPSS version 14.0 (SPSS Inc., Chicago, IL) was used 
for the statistical analysis and p value less than 0.05 was 
considered as statistical signiﬁ  cant.
Results
One hundred patients (50 patients with POAG-group1 and 
50 patients with PEXG-group 2) met the initial inclusion 
criteria of the study. One eye of each subject included in 
the study was randomized to one of the two procedures and 
underwent surgery according to the study protocol. A total 
of seven patients were excluded from the study because of 
intra-operative rupture of posterior capsule and insertion 
of anterior chamber intraocular lens (Table 1). As a result, 
ninety-three patients (47 patients with POAG-group1 and 
46 patients with PEXG-group 2) were ﬁ  nally enrolled in the 
study. The disposition of all study subjects and the baseline 
characteristics of each group are summarized in Table 2 and 
conﬁ  rm that the two groups were similar in age, gender, and 
cup/disc ratio.
Mean IOP, number of medications, and VA were similar 
in POAG and PEXG groups preoperatively (Table 3).
In the POAG group there was no statistically signiﬁ  cant 
difference between the one-site (subgroup 1A) and two-site 
(subgroup 1B) phacotrabeculectomy subgroups, in the mean 
IOP before surgery (p = 0.627; Mann–Whitney test). There 
was also no signiﬁ  cant difference in IOP at all postoperative 
time points including the last follow up (36 months) between 
the two groups, (p = 0.160; Mann–Whitney test) (Figure 1a). 
However, both groups had statistically signiﬁ  cantly less IOP Clinical Ophthalmology 2009:3 300
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postoperatively at 36 months follow-up compared to baseline 
(p = 0.020 and p = 0.023, respectively; Table 4). Mean number 
of supplemental antiglaucoma medications were analogous 
between subgroups 1A and 1B preoperatively (p = 0.826; 
Mann–Whitney test). There was also no statistical signiﬁ  cant 
difference in number of medication between subgroups 1A 
and 1B during the follow-up (Table 5). Ηowever both groups 
needed less medication at 36 months postoperatively compared 
to baseline (p = 0.031, p = 0.032, respectively; Table 4).
Similarly, in PEXG patients there was no statistical 
signiﬁ  cant difference between the one-site (subgroup 2A) 
and two-site (subgroup 2B) phacotrabeculectomy subgroups 
concerning mean IOP preoperatively (p = 0.491; Mann–
Whitney test) and at any interval postoperatively including 
the last follow up (p = 0.216; Mann–Whitney test) 
(Figure 1b). However, mean IOP was statistical signiﬁ  cantly 
less at 36 months postoperatively compared to baseline for 
each subgroup (p = 0.021, p = 0.022, respectively; Table 4). 
The mean number of supplemental antiglaucoma medications 
needed in both subgroups (2A, 2B) in the PEXG group 
before surgery and during follow-up were also similar 
(Table 5). However, each group had a signiﬁ  cant reduction 
in the requirement for antiglaucomatous medication postop-
eratively compared to preoperatively (p = 0.039, p = 0.031, 
respectively; Table 4).
The mean IOP was also similar between subgroups 1A 
and 2A preoperatively and during follow up (Figure 2a). 
The same pattern of IOP variation was observed, when we 
compared subgroups 1B and 2B (Figure 2b).
Overall, the mean IOP and the number of antiglaucomatous 
medications at 36 months postoperatively were not 
statistically different between the four surgical groups 
(p = 0.902 and p = 0.553, respectively; Table 3).
The number of patients not requiring antiglaucomatous 
medication after 36 months follow-up was higher for POAG 
patients (independent of the type of operation) compared 
Table1 Intra- and postoperative complications in one-site and two-site phacotrabeculectomy
POAG (50) PEXG (50)
One-site (1A) Two-site (1B) One-site (2A) Two-site (2B)
Capsular rupture-AC IOL 1 (4%) 2 (8%) 2 (8%) 2 (8%)
Capsular rupture-PC IOL 2 (8.3%) 1 (4.3%) 2 (8.7%) 2 (8.7%)
Conjuctival bleb leaks Early 
( 7 days)
2 (8.3%) 3 (13%) 2 (8.7%) 3 (13%)
Grade 1 Spaeth shallow 
anterior chamber^
0 0 1 (4.3%) 1 (4.3%)
Grade 2 Spaeth shallow 
anterior chamber^
1 (4.2%) 1 (4.3%) 2 (8.7%) 1 (4.3%)
Choroidal effusion 1 (4%) 1 (4.3%) 1 (4.3%) 1 (4.3%)
5-FU 8 (33%) 7 (30%) 12 (52%) 11 (48%)
Bleb encapsulation 1 (4%) 1 (4.3%) 0 1 (4.3%)
N:YAG capsulotomy 6 (25%) 4 (17.4%) 7 (30.4%) 5 (21.7%)
Abbreviations: AC IOL, anterior chamber IOL; IOL, intraocular lens; PC IOL, posterior chamber IOL; PEXG, pseudoexfoliation glaucoma; POAG, primary open-angle 
glaucoma; 5-FU, 5-Fluorouracil.
Note: ^Spaeth grading of shallow anterior chamber.
Table 2 Baseline characteristics for groups treated with one-site or two-site phacotrabeculectomy
POAG PEXG p
One-site (1A) Two-site (1B) One-site (2A) Two-site (2B)
No of patients-eyes 24 23 23 23
Mean age (years) 75.2 ± 4.6 76.3 ± 5.4 74.8 ± 5.3 74.9 ± 4.6 0.881
Range (years) 67–85 68–85 65–89 67–85
Males/Females 11/13 10/13 11/12 10/13 0.989*
Mean C/D ratio 0.66 ± 0.17 0.68 ± 0.15 0.66 ± 0.17 0.68 ± 0.16 0.892
Abbreviations:   ANOVA, analysis of variance; C/D, cup/disc; PEXG, pseudoexfoliation glaucoma; POAG, primary open-angle glaucoma.
Notes: One way ANOVA was performed; *Chi square test.Clinical Ophthalmology 2009:3 301
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to PEXG but this result was not statistically signiﬁ  cant 
(p = 0.150; Table 6).
Concerning the secondary outcome measures between 
groups the VA improved postoperatively compared to 
preoperatively in POAG and PEXG patients who underwent 
either one- or two-site phacotrabeculectomy (Table 4). 
However there was no statistical difference in the ﬁ  nal 
postoperative VA between the four subgroups (p = 0.265; 
Table 3).
There were few complications observed intra-operatively 
and during the follow-up period in the four surgical subgroups 
(Table 1). Laser suturelysis was not performed on any patients. 
One patient from each subgroup (a total of four) had a second 
trabeculectomy for uncontrolled IOP. The second operation 
took place between 18 and 24 months postoperatively. 
Twelve patients with POAG (six from subgroup 1A, six 
from subgroup 1B) and 12 patients with PEXG (seven 
from subgroup 2A, five from subgroup 2B) underwent 
laser capsulotomy (p = 0.257; Chi square test) at 13.2 ± 7.4 
and 12.8 ± 6.5 months after the phacotrabeculectomy, 
respectively. The number of eyes receiving 5-FU injections 
postoperatively was less for POAG patients (with either one-
site or two-site phacotrabeculectomy) compared to PEXG 
patients but this difference was not statistically signiﬁ  cant 
(p = 0.607; Chi square test).
The mean duration of operation was less for one-site 
phacotrabeculectomy compared to two-site phacotrabecu-
lectomy by 9 ± 6 min for both glaucoma groups.
Discussion
Our study focused on the effect of one-site versus two-site 
fornix-based phacotrabeculectomy without the use of antime-
tabolites intraoperatively in two groups of glaucoma patients 
(POAG and PEXG).
Overall, no signiﬁ  cant differences were observed in the 
main outcome measures of IOP and the need for supplemental 
Table 3 Mean IOP, antiglaucoma medication, VA preoperatively and 36 months postoperatively
POAG PEXG p
One-site (1A) Two-site (1B) One-site (2A) Two-site (2B)
IOP preop 22.72 ± 2.17 mmHg 21.36 ± 2.37 mmHg 22.96 ± 2.30 mmHg 22.92 ± 2.45 mmHg 0.823
IOP postop 15.04 ± 1.57 mmHg 15.04 ± 1.99 mmHg 15 ± 1.80 mmHg 15.32 ± 1.31 mmHg 0.902
AM preop 2.84 ± 0.69 2.72 ± 0.79 2.68 ± 0.69 2.80 ± 0.70 0.546
AM postop 0.68 ± 0.69 0.84 ± 0.75 0.96 ± 0.67 0.84 ± 0.62 0.553
VA preop 0.26 ± 0.16 0.26 ± 0.17 0.23 ± 0.14 0.25 ± 0.14 0.882
VA postop 0.60 ± 0.31 0.47 ± 0.28 0.56 ± 0.26 0.60 ± 0.25 0.265
Abbreviations: IOP preop, mean intraocular pressure preoperatively; IOP postop, mean intraocular pressure postoperatively;   AM preop, mean antiglaucoma medication 
preoperatively;   AM postop, mean antiglaucoma medication postoperatively; PEXG, pseudoexfoliation glaucoma; POAG, primary open-angle glaucoma;   VA preop, mean visual 
acuity preoperatively;   VA postop, mean visual acuity postoperatively.














Figure 1a POAG group: Mean IOPs in the one-site and two-site phacotrabeculectomy groups at all time points.
Abbreviations: IOP, intraocular pressure; PEXG, pseudoexfoliation glaucoma; POAG, primary open-angle glaucoma.Clinical Ophthalmology 2009:3 302
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antiglaucoma medications between the two glaucoma groups. 
Both surgical strategies were effective in reducing IOP and 
the mean IOP levels remained stable during the three years 
of follow-up. Both procedures were also able to eliminate 
the need for antiglaucoma medications in many eyes over the 
entire study period. These results suggest that bleb function 
was maintained in a high proportion of all operated eyes.
Two studies comparing one- versus two-site phacotrab-
eculectomy found that at the end of follow-up the one-site 
group required signiﬁ  cantly more medications than the 
two-site group.9,10 In contrast, two other prospective stud-
ies and one retrospective study concluded, similarly to our 
study, that there was no statistical difference in the postop-
erative mean number of glaucoma medications or number 
of patients on glaucoma therapy in one- versus two-site 
phacotrabeculectomy.5,7,11
This study is unique in having compared the outcome of 
combined phacotrabeculectomy speciﬁ  cally in patients with 
PEXG. To the best of our knowledge, our study is the ﬁ  rst 
to analyze separately the outcome of one- versus two-site 
phacotrabeculectomy in PEXG, a type of glaucoma known 
to be more resistant to medical and surgical therapy.
According to our results, the two types of combined 
procedures without the use of antimetabolites intra-operatively 
seem to be equivalent and successful in PEXG patients and 
the outcome is similar to patients with POAG. These ﬁ  ndings 
are consistent with a previous report, where no difference was 
found in the outcome when combined phacotrabeculectomy 
Table 4 Mean IOP, number of antiglaucoma medications, VA preoperatively and 36 months postoperatively in the one-site and two-site 
phacotrabeculectomy in POAG and PEXG patients
POAG PEXG
One-site (1A) p1 Two-site (1B) p2 One-site (2A) p3 Two-site (2B) p4
IOP preop 22.72 ± 2.17 mmHg 0.020 21.36 ± 2.37 mmHg 0.023 22.96 ± 2.30 mmHg 0.021 22.92 ± 2.45 mmHg 0.022
IOP postop 15.04 ± 1.57 mmHg 15.04 ± 1.99 mmHg 15 ± 1.80 mmHg 15.32 ± 1.31 mmHg
AM preop 2.84 ± 0.69 0.031 2.72 ± 0.79 0.032 2.68 ± 0.69 0.039 2.80 ± 0.70 0.031
AM postop  0.68 ± 0.69  0.84 ± 0.75 0.96 ± 0.67 0.84 ± 0.62
VA preop 0.26 0.16 0.001 0.26 0.17 0.003 0.23 0.14 0.001 0.25 0.14 0.001
 VA postop 0.60 0.31 0.47 0.28 0.56 0.26 0.60 0.25
Abbreviations: IOP preop, mean intraocular pressure preoperatively; IOP postop, mean intraocular pressure postoperatively; AM preop, mean antiglaucoma medication 
preoperatively; AM postop, mean antiglaucoma medication postoperatively; PEXG, pseudoexfoliation glaucoma; POAG, primary open-angle glaucoma; VA preop, mean visual 
acuity preoperatively; VA postop, mean visual acuity postoperatively.
Notes: p1, (signiﬁ  cance) comparison in the one-site-POAG group: IOP preop vs IOP postop, AM preop vs AM postop, VA preop vs VA postop; p2 (signiﬁ  cance) comparison 
in the two-site POAG group: IOP preop vs IOP postop, AM preop vs AM postop, VA preop vs VA postop; p3 (signiﬁ  cance) comparison in the one-site PEXG group: IOP preop 
vs IOP postop, AM preop vs AM postop, VA preop vs VA postop; p4 (signiﬁ  cance) comparison in the two-site PEXG group: IOP preop vs IOP postop, AM preop vs AM postop, 
VA preop vs VA postop; Mann–Whitney test.
Table 5 Mean number of antiglaucoma medications in the one-site and two-site phacotrabeculectomy groups at all time points in POAG 
and PEXG patients
AM POAG PEXG p
One-site (1A) Two-site (1B) One-site (2A) Two-site (2B)
Preop 2.84 ± 0.69 2.72 ± 0.80 2.68 ± 0.69 2.80 ± 0.70 0.856
One day postop 0 0 0 0
Seven days postop 0 0 0 0
One month postop 0 0.12 ± 0.33 0.20 ± 0.40 0.16 ± 0.37 0.387
Three months postop 0 0.16 ± 0.37 0. 16 ± 0.37 0.16 ± 0.37 0.973
Six months postop 0.36 ± 0.57 0.64 ± 0.63 0.40 ± 0.58 0.26 ± 0.37 0.051
Two years postop 0.64 ± 0.70 0.84 ± 0.80 0.88 ± 0.66 0.84 ± 0.55 0.601
Three years postop 0.68 ± 0.70 0.84 ± 0.75 0.96 ± 0.67 0.84 ± 0.62 0.553
Abbreviations:   AM, antiglaucoma medication; ANOVA, analysis of variance; PEXG, pseudoexfoliation glaucoma; POAG, primary open-angle glaucoma; preop, preoperatively; 
postop, postoperatively.
Note: One way ANOVA was performed.Clinical Ophthalmology 2009:3 303
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was performed in patients with POAG and PEXG. However, 
in that study mitomycin C was used intraoperatively and only 
one-site surgery was performed.12
In the current study we did ﬁ  nd that two-site surgery 
took statistically signiﬁ  cantly more time, involving changing 
the position and readjusting the microscope, than one-site 
surgery in both glaucoma groups and this is in accordance 
with other studies.5,13
Concerning the intraoperative and postoperative 
complications, they were few and relatively similar in one- 
and two-site phacotrabeculectomy for both POAG and PEXG. 
This result is in accordance with a previous report, where 
there was no signiﬁ  cant difference in the rate of intraoperative 
and postoperative complications in one-site combined 
phacotrabeculectomy between PEXG and non-PEXG eyes, 
although the transition rate to extracapsular cataract extraction 
in eyes with PEXG was found to be higher (but not statisti-
cally signiﬁ  cant).12
Although the two procedures seem to be equivalent in 
terms of the IOP control, reduction in need for antiglaucoma 
medications and improvement in VA, there were some 
differences noted between the two glaucoma groups. Fewer 
patients with POAG (27 patients) required antiglaucoma 
medication at the end of the follow-up compared to patients 
with PEXG (33 patients), although this result was not 
statistically signiﬁ  cant (p   0.05). We expected this result to 
be statistically signiﬁ  cant since PEXG is considered as unpre-













Figure 1b PEXG group: Mean IOPs in the one-site and two-site phacotrabeculectomy groups at all time points.
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Figure 2a One-site phacotrabeculectomy. Mean IOPs in the PEXG and POAG groups at all time points.
Abbreviations: IOP, intraocular pressure; PEXG, pseudoexfoliation glaucoma; POAG, primary open-angle glaucoma.Clinical Ophthalmology 2009:3 304
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Table 6 Eyes not requiring antiglaucoma medication by the end 
of the follow up (three years)
POAG PEXG p
One-site phacotrabeculectomy 11/24 (45.8%) 6/23(26.1%) 0.159
Two-site phacotrabeculectomy 9/23 (39.1%) 7/23 (30.4%) 0.536
Total 20/47 (42.6%) 13/46 (28.3%) 0.150
Abbreviations: PEXG, pseudoexfoliation glaucoma; POAG, primary open-angle 
glaucoma.
Note: Chi square test was performed.
patients from the PEXG group (23 patients) compared to the 
POAG group (15 patients) had IOP   18 mmHg 2–3weeks 
postoperatively and received 5-FU injections (p   0.05). 
We speculated that this more aggressive treatment (use of 
antimetabolites) of these patients at the early postoperative 
period had as a result more effective bleb ﬁ  ltration and 
possibly better control of their IOP in long term (three 
years follow up). In that way the whole group of patients 
with PEXG patients achieved excellent results (mean IOP, 
number of patients requiring antiglaucoma medications 
and mean number of antiglaucoma medications), similar to 
POAG patients. Concerning the number of patients receiving 
5-FU injections we did not observe statistically signiﬁ  cant 
differences between one- and two-site groups independent 
of the type of glaucoma they had, which was in accordance 
with a previous study.14
The good results obtained with combined procedure in 
both treated glaucoma groups, imply that either technique 
may be used to handle the problem of concurrent cataract 
and glaucoma in many patients. Factors that may favor 
a one-site approach are faster surgical time and reduced 
number of corneal incisions. However, there are situations in 
which a two-site approach may be indicated such as surgeon 
familiarity with temporal phacoemulsification, orbital 
anatomy and limited superior access or cases of conjunctival 
scarring limiting the location of the trabeculectomy to a 
site that would make phacoemulsiﬁ  cation through the same 
incision difﬁ  cult.
In conclusion, both approaches can be performed in 
patients with POAG and PEXG with the expectation of 
improved VA and IOP control.
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